These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38061288)

  • 1. Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
    Karuturi MS; Cappelleri JC; Blum JL; Patel K; Telivala B; McCune S; Cuevas JD; Lakhanpal S; Montelongo MZ; Wang Y; Tripathy D; Rocque GB
    J Geriatr Oncol; 2024 Jan; 15(1):101670. PubMed ID: 38061288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
    Blum JL; DiCristo C; Gordon D; Karuturi MS; Oubre D; Jepsen E; Cuevas J; Lakhanpal S; Montelongo MZ; Zhang Z; Cappelleri JC; Wang Y; Tripathy D
    Breast Cancer Res Treat; 2024 Feb; 203(3):463-475. PubMed ID: 37903899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study.
    Meert G; Kenis C; Milisen K; Debruyne PR; De Groof I; Focan C; Cornélis F; Verschaeve V; Bachmann C; Bron D; Den Bulck HV; Schrijvers D; Langenaeken C; Specenier P; Jerusalem G; Praet JP; Lobelle JP; Flamaing J; Wildiers H; Decoster L
    J Geriatr Oncol; 2022 Nov; 13(8):1162-1171. PubMed ID: 36085275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.
    Tripathy D; Blum JL; Rocque GB; Bardia A; Karuturi MS; Cappelleri JC; Liu Y; Zhang Z; Davis KL; Wang Y
    Future Oncol; 2020 Nov; 16(31):2475-2485. PubMed ID: 32787449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
    Agemi Y; Shimokawa T; Sasaki J; Miyazaki K; Misumi Y; Sato A; Aida S; Ishii M; Nakamura Y; Naoki K; Okamoto H
    PLoS One; 2019; 14(1):e0210499. PubMed ID: 30653558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.
    Liposits G; Ryg J; Skuladottir H; Winther SB; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
    J Geriatr Oncol; 2023 Jan; 14(1):101408. PubMed ID: 36494261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
    Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
    Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
    Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer.
    Shah M; Noronha V; Ramaswamy A; Gattani S; Mokal S; Joshi A; Patil V; Menon N; Banavali S; Badwe R; Prabhash K
    J Geriatr Oncol; 2022 Jun; 13(5):720-730. PubMed ID: 35283049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of geriatric screening and assessment in predicting postoperative complications in patients older than 70 years undergoing surgery for colorectal cancer.
    Fagard K; Casaer J; Wolthuis A; Flamaing J; Milisen K; Lobelle JP; Wildiers H; Kenis C
    J Geriatr Oncol; 2017 Sep; 8(5):320-327. PubMed ID: 28781062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?].
    Vazquez L; Arnaud A; Grenier J; Debourdeau P
    Bull Cancer; 2021 May; 108(5):544-552. PubMed ID: 33820647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation and diagnostic value of the Elderly Functional Index version 2.0 for assessing functional status and frailty in older Danish patients with gastrointestinal cancer receiving chemotherapy: A prospective, clinical study.
    Jespersen E; Soo WK; Minet LR; Eshoj HR; King MT; Pfeiffer P; Möller S
    J Geriatr Oncol; 2024 Jan; 15(1):101675. PubMed ID: 38070322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
    Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
    Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Importance of a Detailed Geriatric Functional Assessment of Older Patients with Cancer.
    Baumann C; Baumann R; Wedding U
    Oncol Res Treat; 2021; 44(5):221-231. PubMed ID: 33910204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
    Lynce F; Blackburn MJ; Zhuo R; Gallagher C; Hahn OM; Abu-Khalaf M; Mohebtash M; Wu T; Pohlmann PR; Dilawari A; Tiwari SR; Chitalia A; Warren R; Tan M; Shajahan-Haq AN; Isaacs C
    Cancer; 2021 Oct; 127(19):3622-3630. PubMed ID: 34157782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
    Porte B; Carton M; Lerebours F; Brain E; Loirat D; Haroun L; Bellesoeur A; Bach Hamba S; Kirova Y; Cottu P
    Breast; 2020 Dec; 54():303-310. PubMed ID: 33242757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
    Lee J; Park HS; Won HS; Yang JH; Lee HY; Woo IS; Shin K; Hong JH; Yang YJ; Chun SH; Byun JH
    Cancer Res Treat; 2021 Apr; 53(2):409-423. PubMed ID: 33138346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
    Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
    Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.